Overall survival: Median length of · women with early breast cancer
OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).
1 finding from 1 review
Disease-free survival · women with early breast cancer
OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).
1 finding from 1 review
Toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade" toxicity) · women with early breast cancer
OFS may leads to higher toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade"… compared with no OFS (low certainty).
1 finding from 1 review
Toxicity ‐ mood · women with early breast cancer
1 finding from 1 review
Toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) · women with early breast cancer
OFS may leads to higher toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) compared with no OFS (low certainty).
1 finding from 1 review
Contralateral breast cancer · women with early breast cancer
OFS probably leads to lower contralateral breast cancer compared with no OFS (moderate certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Mortality before hospital discharge · Parenterally fed preterm infants
MOFS‐LE showed no clear difference in death before discharge compared with S‐LE (low certainty).
1 finding from 1 review
Days to regain birth weight · Parenterally fed preterm infants
1 finding from 1 review
Rate of weight gain (g/kg/day) · Parenterally fed preterm infants
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
MOFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
1 finding from 1 review
Any sepsis (clinical and/or culture positive) · Parenterally fed preterm infants
MOFS‐LE showed no clear difference in any sepsis (clinical and/or culture positive) compared with S‐LE (low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · Parenterally fed preterm infants
MOFS‐LE showed no clear difference in retinopathy of prematurity (≥ stage 3) compared with S‐LE (low certainty).
1 finding from 1 review
Parenteral nutrition‐associated liver disease/cholestasis · Parenterally fed preterm infants
MOFS‐LE showed no clear difference in parenteral nutrition‐associated liver disease/cholestasis compared with S‐LE (low certainty).
1 finding from 1 review
Growth · Parenterally fed preterm infants
1 finding from 1 review
Growth · Parenterally fed preterm infants
1 finding from 1 review
PNALD/cholestasis (conjugated bilirubin ≥ 2 mg/dL) – MOFS‐LE vs MFS‐LE · Parenterally fed preterm infants
Fish oil lipid emulsion (LE) showed no clear difference in PNALD/cholestasis (conjugated bilirubin ≥ 2 mg/dL) – MOFS‐LE vs MFS‐LE compared with another fish oil LE (low certainty).
1 finding from 1 review
Death at hospital discharge · Parenterally fed preterm infants
Fish oil lipid emulsion (LE) showed no clear difference in death before discharge – MOFS‐LE vs MFS‐LE compared with another fish oil LE (low certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · Parenterally fed preterm infants
Fish oil lipid emulsion (LE) showed no clear difference in CLD (oxygen requirement at 36 weeks' postmenstrual age) – MOFS‐LE vs… compared with another fish oil LE (low certainty).
1 finding from 1 review
Any sepsis (clinical and/or culture positive) · Parenterally fed preterm infants
Fish oil lipid emulsion (LE) showed no clear difference in any sepsis (clinical or culture positive (or both)) – MOFS‐LE vs… compared with another fish oil LE (low certainty).
1 finding from 1 review